Literature DB >> 16407111

A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.

Robert B West1, Brian P Rubin, Melinda A Miller, Subbaya Subramanian, Gulsah Kaygusuz, Kelli Montgomery, Shirley Zhu, Robert J Marinelli, Alessandro De Luca, Erinn Downs-Kelly, John R Goldblum, Christopher L Corless, Patrick O Brown, C Blake Gilks, Torsten O Nielsen, David Huntsman, Matt van de Rijn.   

Abstract

Tenosynovial giant-cell tumor (TGCT) and pigmented villonodular synovitis (PVNS) are related conditions with features of both reactive inflammatory disorders and clonal neoplastic proliferations. Chromosomal translocations involving chromosome 1p13 have been reported in both TGCT and PVNS. We confirm that translocations involving 1p13 are present in a majority of cases of TGCT and PVNS and show that CSF1 is the gene at the chromosome 1p13 breakpoint. In some cases of both TGCT and PVNS, CSF1 is fused to COL6A3 (2q35). The CSF1 translocations result in overexpression of CSF1. In cases of TGCT and PVNS carrying this translocation, it is present in a minority of the intratumoral cells, leading to CSF1 expression only in these cells, whereas the majority of cells express CSF1R but not CSF1, suggesting a tumor-landscaping effect with aberrant CSF1 expression in the neoplastic cells, leading to the abnormal accumulation of nonneoplastic cells that form a tumorous mass.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407111      PMCID: PMC1325107          DOI: 10.1073/pnas.0507321103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

3.  Molecular characterisation of soft tissue tumours: a gene expression study.

Authors:  Torsten O Nielsen; Rob B West; Sabine C Linn; Orly Alter; Margaret A Knowling; John X O'Connell; Shirley Zhu; Mike Fero; Gavin Sherlock; Jonathan R Pollack; Patrick O Brown; David Botstein; Matt van de Rijn
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

4.  Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

Authors:  Brian P Rubin; Scott M Schuetze; Janet F Eary; Thomas H Norwood; Sohail Mirza; Ernest U Conrad; James D Bruckner
Journal:  J Clin Oncol       Date:  2002-09-01       Impact factor: 44.544

5.  Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors.

Authors:  M Nilsson; M Höglund; I Panagopoulos; R Sciot; P Dal Cin; M Debiec-Rychter; F Mertens; N Mandahl
Journal:  Virchows Arch       Date:  2002-04-13       Impact factor: 4.064

6.  Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans.

Authors:  Sabine C Linn; Rob B West; Jonathan R Pollack; Shirley Zhu; Tina Hernandez-Boussard; Torsten O Nielsen; Brian P Rubin; Rajiv Patel; John R Goldblum; David Siegmund; David Botstein; Patrick O Brown; C Blake Gilks; Matt van de Rijn
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

7.  SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Authors:  Lesley J Murray; Tinya J Abrams; Kelly R Long; Theresa J Ngai; Lisa M Olson; Weiru Hong; Paul K Keast; Jacqueline A Brassard; Anne Marie O'Farrell; Julie M Cherrington; Nancy K Pryer
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 8.  Regulation of myeloid development and function by colony stimulating factors.

Authors:  Daniel R Barreda; Patrick C Hanington; Miodrag Belosevic
Journal:  Dev Comp Immunol       Date:  2004-05-03       Impact factor: 3.636

9.  Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Christopher L Corless; George D Demetri; Charles D Blanke; Margaret von Mehren; Heikki Joensuu; Laura S McGreevey; Chang-Jie Chen; Annick D Van den Abbeele; Brian J Druker; Beate Kiese; Burton Eisenberg; Peter J Roberts; Samuel Singer; Christopher D M Fletcher; Sandra Silberman; Sasa Dimitrijevic; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2003-12-01       Impact factor: 44.544

10.  Determination of stromal signatures in breast carcinoma.

Authors:  Robert B West; Dimitry S A Nuyten; Subbaya Subramanian; Torsten O Nielsen; Christopher L Corless; Brian P Rubin; Kelli Montgomery; Shirley Zhu; Rajiv Patel; Tina Hernandez-Boussard; John R Goldblum; Patrick O Brown; Marc van de Vijver; Matt van de Rijn
Journal:  PLoS Biol       Date:  2005-05-10       Impact factor: 8.029

View more
  118 in total

1.  Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions.

Authors:  Brian P Rubin
Journal:  Skeletal Radiol       Date:  2007-04       Impact factor: 2.199

2.  Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.

Authors:  William D Tap; Hans Gelderblom; Emanuela Palmerini; Jayesh Desai; Sebastian Bauer; Jean-Yves Blay; Thierry Alcindor; Kristen Ganjoo; Javier Martín-Broto; Christopher W Ryan; David M Thomas; Charles Peterfy; John H Healey; Michiel van de Sande; Heather L Gelhorn; Dale E Shuster; Qiang Wang; Antoine Yver; Henry H Hsu; Paul S Lin; Sandra Tong-Starksen; Silvia Stacchiotti; Andrew J Wagner
Journal:  Lancet       Date:  2019-06-19       Impact factor: 79.321

3.  Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers.

Authors:  Ashish B Rajput; Melinda A Miller; Alessandro De Luca; Niki Boyd; Sam Leung; Antonio Hurtado-Coll; Ladan Fazli; Edward C Jones; Jodie B Palmer; Martin E Gleave; Michael E Cox; David G Huntsman
Journal:  J Clin Pathol       Date:  2007-01-26       Impact factor: 3.411

4.  Molecular biology and therapeutics in musculoskeletal oncology.

Authors:  Theresa A Guise; Regis O'Keefe; R Lor Randall; Richard M Terek
Journal:  J Bone Joint Surg Am       Date:  2009-03-01       Impact factor: 5.284

5.  Wegener's granulomatosis and giant cell tumor of tendon sheaths: casual or causal combination? First case report.

Authors:  Francesco De Leonardis; Renato La Corte; Marco Bruschi; Luigi Cavazzini; Francesco Trotta
Journal:  Rheumatol Int       Date:  2009-04-10       Impact factor: 2.631

6.  Localized tenosynovial giant cell tumor in both knee joints.

Authors:  Hyun Su Kim; Jong Won Kwon; Jin Hwan Ahn; Moon Jong Chang; Eun Yoon Cho
Journal:  Skeletal Radiol       Date:  2010-03-31       Impact factor: 2.199

7.  Pigmented villonodular synovitis responsive to imatinib therapy.

Authors:  Wynne M Snoots; David Watkins; Dee Dockery; Robert Mennel; Brennen Scott Cheek
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

8.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

9.  Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma.

Authors:  Inigo Espinosa; Andrew H Beck; Cheng-Han Lee; Shirley Zhu; Kelli D Montgomery; Robert J Marinelli; Kristen N Ganjoo; Torsten O Nielsen; C Blake Gilks; Robert B West; Matt van de Rijn
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

10.  The macrophage colony-stimulating factor 1 response signature in breast carcinoma.

Authors:  Andrew H Beck; Inigo Espinosa; Badreddin Edris; Rui Li; Kelli Montgomery; Shirley Zhu; Sushama Varma; Robert J Marinelli; Matt van de Rijn; Robert B West
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.